Mary Anne Rossing
Overview
Explore the profile of Mary Anne Rossing including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
134
Citations
5482
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dareng E, Coetzee S, Tyrer J, Peng P, Rosenow W, Chen S, et al.
Am J Hum Genet
. 2024 May;
111(6):1061-1083.
PMID: 38723632
To identify credible causal risk variants (CCVs) associated with different histotypes of epithelial ovarian cancer (EOC), we performed genome-wide association analysis for 470,825 genotyped and 10,163,797 imputed SNPs in 25,981...
2.
Dareng E, Tyrer J, Barnes D, Jones M, Yang X, Aben K, et al.
Eur J Hum Genet
. 2022 Mar;
30(5):630-631.
PMID: 35314806
No abstract available.
3.
Dareng E, Tyrer J, Barnes D, Jones M, Yang X, Aben K, et al.
Eur J Hum Genet
. 2022 Jan;
30(3):349-362.
PMID: 35027648
Polygenic risk scores (PRS) for epithelial ovarian cancer (EOC) have the potential to improve risk stratification. Joint estimation of Single Nucleotide Polymorphism (SNP) effects in models could improve predictive performance...
4.
Brieger K, Phung M, Mukherjee B, Bakulski K, Anton-Culver H, Bandera E, et al.
Cancer Epidemiol Biomarkers Prev
. 2021 Nov;
31(2):443-452.
PMID: 34789471
Background: There is suggestive evidence that inflammation is related to ovarian cancer survival. However, more research is needed to identify inflammation-related factors that are associated with ovarian cancer survival and...
5.
Lee A, Rosenzweig S, Wiensch A, Ramus S, Menon U, Gentry-Maharaj A, et al.
J Natl Cancer Inst
. 2020 Aug;
113(3):301-308.
PMID: 32766851
Background: Parity is associated with decreased risk of invasive ovarian cancer; however, the relationship between incomplete pregnancies and invasive ovarian cancer risk is unclear. This relationship was examined using 15...
6.
Brieger K, Peterson S, Lee A, Mukherjee B, Bakulski K, Alimujiang A, et al.
Gynecol Oncol
. 2020 Jul;
158(3):702-709.
PMID: 32641237
Purpose: Prior studies of menopausal hormone therapy (MHT) and ovarian cancer survival have been limited by lack of hormone regimen detail and insufficient sample sizes. To address these limitations, a...
7.
Talhouk A, George J, Wang C, Budden T, Tan T, Chiu D, et al.
Clin Cancer Res
. 2020 Jun;
26(20):5411-5423.
PMID: 32554541
Purpose: Gene expression-based molecular subtypes of high-grade serous tubo-ovarian cancer (HGSOC), demonstrated across multiple studies, may provide improved stratification for molecularly targeted trials. However, evaluation of clinical utility has been...
8.
Song H, Dicks E, Tyrer J, Intermaggio M, Chenevix-Trench G, Bowtell D, et al.
J Med Genet
. 2020 Jun;
58(5):305-313.
PMID: 32546565
Purpose: The known epithelial ovarian cancer (EOC) susceptibility genes account for less than 50% of the heritable risk of ovarian cancer suggesting that other susceptibility genes exist. The aim of...
9.
Babic A, Sasamoto N, Rosner B, Tworoger S, Jordan S, Risch H, et al.
JAMA Oncol
. 2020 Apr;
6(6):e200421.
PMID: 32239218
Importance: Breastfeeding has been associated with a reduced risk of epithelial ovarian cancer in multiple studies, but others showed no association. Whether risk reduction extends beyond that provided by pregnancy...
10.
Lee A, Wu A, Wiensch A, Mukherjee B, Terry K, Harris H, et al.
Epidemiology
. 2020 Feb;
31(3):402-408.
PMID: 32028322
Background: Menopausal estrogen-alone therapy is a risk factor for endometrial and ovarian cancers. When a progestin is included with the estrogen daily (continuous estrogen-progestin combined therapy), there is no increased...